RxDoctor Payments Data

Curtis Whiting, MD

Pulmonary Disease · Kansas City, MONPI 1477993921

Payments from drug & device makers

$611in general payments, 2019–2025

Across 24 payments — averaging $25.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$199
  • Boehringer Ingelheim$65
  • UCB, Inc.$55
  • GSK$49
  • Mylan Specialty L.p.$42
  • Paratek Pharmaceuticals, Inc.$33
  • plus $167 from 9 others

What the payments were for

  • Food & beverage$59397%
  • Education$173%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$611 in reported general payments places this provider in the 35th percentile of 295 pulmonary disease providers in Missouri.

See all pulmonary disease providers in Missouri

Medicare billing

Part B allowed, 2024
$98,571
Medicare patients
417
Services billed
1,035

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter289$225,188
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr152$87,013
Breo ElliptaFluticasone/Vilanterol188$83,846
Stiolto RespimatTiotropium Br/Olodaterol Hcl63$42,366
Spiriva RespimatTiotropium Bromide20$19,520
Breztri AerosphereBudesonide/Glycopyr/Formoterol24$13,758
Incruse ElliptaUmeclidinium Bromide27$9,909
Spiriva HandihalerTiotropium Bromide13$9,531
Advair HfaFluticasone Propion/Salmeterol25$9,409
Albuterol Sulfate HfaAlbuterol Sulfate211$6,837
Bevespi AerosphereGlycopyrrolate/Formoterol Fum13$6,575
SymbicortBudesonide/Formoterol Fumarate12$4,080
Fluticasone-SalmeterolFluticasone Propion/Salmeterol16$3,029
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate22$3,019
Roflumilast23$1,731

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta$49$405,955656 claims
Boehringer IngelheimStiolto Respimat, Spiriva Respimat$65$61,88583 claims
AstraZenecaBreztri Aerosphere, Bevespi Aerosphere, Symbicort$199$24,41349 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 295 pulmonary disease providers in Missouri.

Other pulmonary disease in Kansas City

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →